In one paragraphReview in Medical sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Ekaterina A LesovayaLaboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia.ORCID 0000-0002-1967-9637 Timur I FetisovLaboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia.
Beniamin Yu BokhyanLaboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia.
Varvara P MaksimovaLaboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia.ORCID 0000-0003-0896-2952 Evgeny P KulikovFaculty of Oncology, I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia, 9 Vysokovol'tnaya St., Ryazan 390026, Russia.
Gennady A BelitskyLaboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia.
Kirill I KirsanovLaboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia.ORCID 0000-0002-8599-6833 Marianna G YakubovskayaLaboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia.ORCID 0000-0002-9710-8178 Funding
Russian Science Foundation 23-65-00003
6 · The paper itselfAbstract
Leiomyosarcoma (LMS) is a rare, aggressive soft-tissue sarcoma arising from smooth muscle cells. It has a high metastatic potential and limited therapeutic options. Despite advances in oncology, the molecular landscape of LMS remains incompletely understood, particularly regarding the genetic and epigenetic alterations that affect key signaling pathways. This review summarizes the current knowledge of mechanisms driving LMS pathogenesis, including somatic mutations in genes such as
Indexed as
LeiomyosarcomaChromosomal InstabilityEpigenesis, GeneticHumansMutationSignal Transductionamplificationchromosomal translocationepigenetic changesgenetic heterogeneitygenome instabilityimmunotherapyleiomyosarcomamutationsignaling alteration
Identifiers
PMID42783444
PMCPMC13609683
What OpenQuestion holds
Textmetadata
Read underepoch 390